U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C38H73N21O10S2
Molecular Weight 1048.251
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETELCALCETIDE

SMILES

C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O

InChI

InChIKey=ANIAZGVDEUQPRI-ZJQCGQFWSA-N
InChI=1S/C38H73N21O10S2/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52)/t18-,19-,21+,22-,23-,24-,25-,26-/m1/s1

HIDE SMILES / InChI

Description

Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. Etelcalcetide is a synthetic peptide calcium-sensing receptor agonist. It allosterically modulates the calcium-sensing receptor (CaSR). Etelcalcetide binds to the CaSR and enhances activation of the receptor by extracellular calcium. Activation of the CaSR on parathyroid chief cells decreases PTH secretion.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
25.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Parsabiv
PubMed

PubMed

TitleDatePubMed
Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
2017 Dec
A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism.
2017 Jul
Formulary Drug Review: Etelcalcetide.
2017 Nov
Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.
2017 Sep
A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet.
2018 May
Patents

Sample Use Guides

In Vivo Use Guide
 Ensure corrected serum calcium is at or above the lower limit of normal prior to PARSABIV (Etelcalcetide) initiation, a PARSABIV dose increase, or re-initiation of PARSABIV therapy after a dosing interruption.  The recommended starting dose of PARSABIV is 5 mg administered by intravenous (IV) bolus injection three times per week at the end of hemodialysis treatment.  The maintenance dose of PARSABIV is individualized and determined by titration based on parathyroid hormone (PTH) and corrected serum calcium response. The maintenance dose is the dose that maintains PTH levels within the recommended target range and corrected serum calcium within the normal range. The lowest maintenance dose of PARSABIV is 2.5 mg three times per week and the highest maintenance dose of PARSABIV is 15 mg three times per week.  Administer PARSABIV only at the end of hemodialysis treatment.  If a regularly scheduled hemodialysis treatment is missed, DO NOT administer any missed doses. Resume PARSABIV at the end of the next hemodialysis treatment at the prescribed dose. If doses of PARSABIV are missed for more than 2 weeks, re-initiate PARSABIV at the recommended starting dose of 5 mg (or 2.5 mg if that was the patient’s last dose).
Route of Administration: Intravenous
In Vitro Use Guide
Treatment of HEK-293T cells expressing the hCaSR with increasing concentrations of Etelcalcetide (AMG 416) resulted in a dose-dependent increase in IP1 accumulation with an apparent EC50 of 25 uM.
Name Type Language
ETELCALCETIDE
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
TELCALCETIDE
Common Name English
ETELCALCETIDE [WHO-DD]
Common Name English
ONO-5163
Code English
VELCALCETIDE
Common Name English
N-ACETYL-D-CYSTEINYL-D-ALANYL-D-ARGINYL-D-ARGINYL-D-ARGINYL-D-ALANYL-D-ARGININAMIDE DISULFIDE WITH L-CYSTEINE
Common Name English
ETELCALCETIDE [INN]
Common Name English
KAI-4169
Code English
PARSABIV
Brand Name English
ETELCALCETIDE [USAN]
Common Name English
D-ARGININAMIDE, N-ACETYL-D-CYSTEINYL-D-ALANYL-D-ARGINYL-D-ARGINYL-D-ARGINYL-D-ALANYL-, DISULFIDE WITH L-CYSTEINE
Common Name English
AMG-416
Code English
Classification Tree Code System Code
WHO-ATC H05BX04
Created by admin on Tue Mar 06 10:42:59 UTC 2018 , Edited by admin on Tue Mar 06 10:42:59 UTC 2018
Code System Code Type Description
PUBCHEM
71511839
Created by admin on Tue Mar 06 10:42:59 UTC 2018 , Edited by admin on Tue Mar 06 10:42:59 UTC 2018
PRIMARY SWITZERF
EVMPD
SUB178987
Created by admin on Tue Mar 06 10:42:59 UTC 2018 , Edited by admin on Tue Mar 06 10:42:59 UTC 2018
PRIMARY
ChEMBL
CHEMBL3545184
Created by admin on Tue Mar 06 10:42:59 UTC 2018 , Edited by admin on Tue Mar 06 10:42:59 UTC 2018
PRIMARY
EPA CompTox
1262780-97-1
Created by admin on Tue Mar 06 10:42:59 UTC 2018 , Edited by admin on Tue Mar 06 10:42:59 UTC 2018
PRIMARY
NCI_THESAURUS
C129712
Created by admin on Tue Mar 06 10:42:59 UTC 2018 , Edited by admin on Tue Mar 06 10:42:59 UTC 2018
PRIMARY
CAS
1262780-97-1
Created by admin on Tue Mar 06 10:42:59 UTC 2018 , Edited by admin on Tue Mar 06 10:42:59 UTC 2018
PRIMARY
INN
9809
Created by admin on Tue Mar 06 10:42:59 UTC 2018 , Edited by admin on Tue Mar 06 10:42:59 UTC 2018
PRIMARY
RXCUI
1876119
Created by admin on Tue Mar 06 10:42:59 UTC 2018 , Edited by admin on Tue Mar 06 10:42:59 UTC 2018
PRIMARY